Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Infection ; 48(6): 853-860, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32462287

ABSTRACT

PURPOSE: Microbial dysbiosis has been found preceding necrotizing enterocolitis (NEC) in preterm infants; thus, we aimed to investigate whether there is evidence that neonates with extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) positive stool cultures are at higher risk for NEC at the NICU. METHODS: We included very preterm inborn infants of ≤ 32 weeks of gestational age being fecal carriers of ESBL-E and compared them with 1:1 matched (gestational age, birth weight, gender and year) controls tested negative for ESBL-E in the stool between 2005 and 2016. An association with NEC was defined as the first detection of ESBL-E before or at the time of definite diagnosis of NEC. RESULTS: During the study period, we diagnosed 217 infants with a total of 270 ESBL-E. We identified ten different species with ESBL-producing Klebsiella oxytoca being the most common one (46%) followed by Klebsiella pneumoniae (19%), and Citrobacter freundii (17%). Ten out of 217 infants had any kind of NEC in the case group compared to two of the controls (p < 0.01), but only four cases with predefined criteria were associated with NEC ≥ stage IIa (1.8 vs. 0.5%, p = 0.089, OR 4.1, CI95% 0.45-36.6). NEC mortality rate was 2/8 (25%). CONCLUSIONS: We observed a threefold increase of ESBL-E in stool surveillance cultures during study time and germs were dominated by ESBL-producing Klebsiella spp. There was no evidence that preterm infants colonized with ESBL-E in the stool were at higher risk for definite NEC.


Subject(s)
Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae/isolation & purification , Enterocolitis, Necrotizing/epidemiology , Feces/microbiology , beta-Lactamases/analysis , Austria/epidemiology , Case-Control Studies , Enterobacteriaceae/metabolism , Enterobacteriaceae Infections/microbiology , Enterocolitis, Necrotizing/microbiology , Female , Humans , Incidence , Infant, Newborn , Infant, Premature , Intensive Care Units, Neonatal , Male , Retrospective Studies , Risk Factors
2.
Support Care Cancer ; 28(5): 2157-2161, 2020 May.
Article in English | MEDLINE | ID: mdl-31410599

ABSTRACT

A 5-year-old patient treated for acute lymphoblastic leukaemia (ALL) developed proven pulmonary invasive fungal disease (IFD) due to Actinomucor elegans. While completing ALL treatment according to AIEOP ALL protocol 2009 for further 15 months, antifungal treatment with liposomal amphotericin B and intermittent additional posaconazole was continued until immune reconstitution 7 months after the end of ALL treatment. Repeated imaging guided treatment decisions. Twenty-six and 19 months after the end of ALL treatment and antifungal treatment, respectively, the patient is still in the first complete remission and shows no signs of active invasive fungal disease (IFD).


Subject(s)
Amphotericin B/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Invasive Fungal Infections/drug therapy , Lung Diseases, Fungal/drug therapy , Mucormycosis/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Antifungal Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Asparaginase/administration & dosage , Child, Preschool , Cyclophosphamide/administration & dosage , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Humans , Lung Diseases, Fungal/microbiology , Male , Mercaptopurine/administration & dosage , Methotrexate/administration & dosage , Mucorales/isolation & purification , Precursor Cell Lymphoblastic Leukemia-Lymphoma/microbiology , Prednisone/administration & dosage , Remission Induction , Triazoles/therapeutic use , Vincristine/administration & dosage
3.
Eur J Pediatr ; 178(12): 1923-1927, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31506723

ABSTRACT

Child health has improved considerably, partly due to increased availability of appropriate disease surveillance and treatment. Inappropriate testing and treatment may impose a risk. There is a large and unexplained variation in the use of tests and treatments for children between and within countries. This suggests that non-scientific factors determine their use. In an era of increasing availability of health services, pediatricians have an important role in balancing risks and benefits of available tests and treatments. Examples from the medical literature of overtesting and overtreatment challenge us to reconsider current practices. Antibiotic overuse, overtreatment of bronchiolitis, and non-indicated radiological procedures are found in common practice across Europe. Choosing Wisely is an initiative to improve the quality of care by reducing unnecessary testing and treatment.Conclusion: Clinicians have the challenge to find the optimal balance between too much and too little medicine-just appropriate.


Subject(s)
Decision Making , Medical Overuse/prevention & control , Antimicrobial Stewardship , Child , Diagnostic Imaging , Europe , Humans , Practice Guidelines as Topic , Proton Pump Inhibitors/therapeutic use , Vitamin D Deficiency/diagnosis
4.
Front Pediatr ; 10: 744182, 2022.
Article in English | MEDLINE | ID: mdl-35601438

ABSTRACT

Background: Pediatric osteoarticular infections (POAIs) are serious diseases requiring early diagnosis and treatment. Methods: In this prospective multicenter cohort study, children with POAIs were selected from the European Union Childhood Life-threatening Infectious Diseases Study (EUCLIDS) database to analyze their demographic, clinical, and microbiological data. Results: A cohort of 380 patients with POAIs, 203 with osteomyelitis (OM), 158 with septic arthritis (SA), and 19 with both OM and SA, was analyzed. Thirty-five patients were admitted to the Pediatric Intensive Care Unit; out of these, six suffered from shock, one needed an amputation of the right foot and of four left toes, and two had skin transplantation. According to the Pediatric Overall Performance Score, 36 (10.5%) showed a mild overall disability, 3 (0.8%) a moderate, and 1 (0.2%) a severe overall disability at discharge. A causative organism was detected in 65% (247/380) of patients. Staphylococcus aureus (S. aureus) was identified in 57.1% (141/247) of microbiological confirmed cases, including 1 (0.7%) methicillin-resistant S. aureus (MRSA) and 6 (4.2%) Panton-Valentine leukocidin (PVL)-producing S. aureus, followed by Group A Streptococcus (18.2%) and Kingella kingae (8.9%). K. kingae and PVL production in S. aureus were less frequently reported than expected from the literature. Conclusion: POAIs are associated with a substantial morbidity in European children, with S. aureus being the major detected pathogen. In one-third of patients, no causative organism is identified. Our observations show an urgent need for the development of a vaccine against S. aureus and for the development of new microbiologic diagnostic guidelines for POAIs in European pediatric hospitals.

5.
Pediatr Infect Dis J ; 40(9): 835-837, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34260495

ABSTRACT

We performed a retrospective case-control cohort study following 146 preterm infants (≤32 weeks of gestation) who had been colonized with extended spectrum beta-lactamase producing Enterobacterales and compared them with 1:1 matched controls regarding rates of hospitalizations and outpatient visits because of infectious and gastrointestinal diseases and developmental impairment up to school age. Preterm infants with extended spectrum beta-lactamase producing Enterobacterales colonization did have neither higher rates of gastrointestinal or infectious diseases nor higher rates of developmental impairments up to the age of 6 years.


Subject(s)
Enterobacteriaceae/physiology , beta-Lactamases/genetics , Carrier State/microbiology , Case-Control Studies , Child , Child, Preschool , Cross Infection/microbiology , Enterobacteriaceae/enzymology , Enterobacteriaceae/genetics , Enterobacteriaceae Infections/microbiology , Follow-Up Studies , Gestational Age , Humans , Infant , Infant, Newborn , Infant, Premature , Retrospective Studies , beta-Lactamases/biosynthesis
6.
Pediatr Infect Dis J ; 37(11): e273-e275, 2018 11.
Article in English | MEDLINE | ID: mdl-29634619

ABSTRACT

We describe herein the management of a 16-year-old girl with cystic echinococcosis of the right ventricle and massive obstruction of the pulmonary vessel system by parasitic metastatic dissemination. After resection of the cardiac cyst, pulmonary thromboendarterectomy was performed to remove parts of the obstructive parasitic material. The treatment reduced the elevated pulmonary arterial pressure, improving the patient's overall condition.


Subject(s)
Echinococcosis/complications , Heart Ventricles/parasitology , Lung Diseases, Obstructive/parasitology , Adolescent , Albendazole/therapeutic use , Anthelmintics/therapeutic use , Echinococcosis/drug therapy , Endarterectomy , Female , Humans , Lung/parasitology , Lung/pathology , Lung Diseases, Obstructive/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL